U.S. FDA nod for Aurobindo’s Droxidopa capsules
The Hindu
Drugmaker Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (US FDA) to manufacture and market Droxidopa capsules, 100 mg, 200 mg and 300 mg.
Droxidopa Capsules are generic version of Lundbeck NA’s Northera capsules and will be launched immediately, the company said on Friday. The approved product has an estimated market size of $352 million for the 12 months ending December 2020, a release said quoting IQVIA numbers.
More Related News
According to BACL, the biophilic-inspired business park will offer smart workspaces within a vibrant public realm. The project’s most exceptional and breathtaking attribute lies in the Urban Forest, a lush oasis in the centre of the development. This green space will serve as a focal point, seamlessly blending indoor and outdoor spaces throughout the area. The upcoming metro station in Airport City will provide seamless connectivity to the business park from the northern side, ensuring convenient accessibility.